MSH2 and colonic neoplasm: To assess if MSH2 mutant human colon cancer cells respond to this drug we examined LoVo (ATCC) and found this line to be sensitive to the drug as well, as determined by CellTiter96®AQueousAssay (Promega) (Fig. 1A).